dr. kuykendall on the impact of ruxolitinib in myeloproliferative neoplasms
Published 5 years ago • 433 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:31
dr. kuykendall on toxicity profiles of ruxolitinib and fedratinib in myelofibrosis
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
2:10
aacr 2021 - dr. andrew kuykendall - abstract ct236
-
1:10
dr. bradley on ruxolitinib in myeloproliferative neoplasms
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
4:11
impact of ruxolitinib approval on myelofibrosis real-world survival in the us
-
1:05
the role of ruxolitinib in myeloproliferative neoplasms
-
6:42
differentiating between myeloproliferative neoplasms
-
2:16
the current state-of-the-art in mf and pv therapy and future outlooks
-
4:09
risk factors for progression in mpns
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
1:25
dr. bose on the utility of ruxolitinib in myelofibrosis
-
1:08
dr. kiladjian on ruxolitinib plus interferon in mpns
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
0:52
maureen e. thyne discusses ruxolitinib's impact on myelofibrosis
-
0:56
dr. saint fleur-lominy on the use of ruxolitinib versus fedratinib in mpns
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment